TICKERNOMICS Sign up
Last Update: 2024-03-28 02:14:05
Calidi Biotherapeutics Inc. ( CLDI )
0.57USD
Sector:
Healthcare
Industry:
Biotechnology
Country:
1y
3y
5y
10y
Historical Returns*:
SPY
31.15%
-94.44%
CLDI
SPY
32.74%
CLDI
0.00%
SPY
92.93%
CLDI
0.00%
SPY
224.41%
CLDI
0.00%
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
21.36
23.48
0.06
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
EV/EBITDA
-0.74
0.00
-2.59
-5.23
0.00
-0.91
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
0.00
0.00
0.00
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Beta
4.27
132.90
128.61
0.00
Other Earnings and Cash Flow Stats:
Calidi Biotherapeutics Inc. ( CLDI ) Net Income TTM ($MM) is -21.60
Calidi Biotherapeutics Inc. ( CLDI ) Operating Income TTM ($MM) is -27.49
Calidi Biotherapeutics Inc. ( CLDI ) Owners' Earnings Annual ($MM) is 0.00
Calidi Biotherapeutics Inc. ( CLDI ) Current Price to Owners' Earnings ratio is 0.00
Calidi Biotherapeutics Inc. ( CLDI ) EBITDA TTM ($MM) is -27.09
Calidi Biotherapeutics Inc. ( CLDI ) EBITDA Margin is 0.00%
Capital Allocation:
Calidi Biotherapeutics Inc. ( CLDI ) has paid 0.00 dividends per share and bought back -26.938 million shares in the past 12 months
Calidi Biotherapeutics Inc. ( CLDI ) has increased its debt by 3.723 million USD in the last 12 months
Capital Structure:
Calidi Biotherapeutics Inc. ( CLDI ) Interest-bearing Debt ($MM) as of last quarter is 4
Calidi Biotherapeutics Inc. ( CLDI ) Annual Working Capital Investments ($MM) are 35
Calidi Biotherapeutics Inc. ( CLDI ) Book Value ($MM) as of last quarter is -9
Calidi Biotherapeutics Inc. ( CLDI ) Debt/Capital as of last quarter is -50%
Other Balance Sheet Stats:
Calidi Biotherapeutics Inc. ( CLDI ) has 1 million in cash on hand as of last quarter
Calidi Biotherapeutics Inc. ( CLDI ) has 10 million of liabilities due within 12 months, and long term debt 2 as of last quarter
Calidi Biotherapeutics Inc. ( CLDI ) has 35 common shares outstanding as of last quarter
Calidi Biotherapeutics Inc. ( CLDI ) has 0 million USD of preferred stock value
Academic Scores:
Calidi Biotherapeutics Inc. ( CLDI ) Altman Z-Score is -22.52 as of last quarter
Calidi Biotherapeutics Inc. ( CLDI ) Piotroski Score is 3.00 as of last quarter
Corporate Governance:
Calidi Biotherapeutics Inc. ( CLDI ) largest shareholder is owning shares at 0.00 ($MM) value
(an insider) shares of Calidi Biotherapeutics Inc. ( CLDI ) for the amount of $ on
0.00% of Calidi Biotherapeutics Inc. ( CLDI ) is held by insiders, and 99.94% is held by institutions
Calidi Biotherapeutics Inc. ( CLDI ) went public on 2021-11-01
Other Calidi Biotherapeutics Inc. ( CLDI ) financial metrics:
FCF:-15.61
Unlevered Free Cash Flow:-58.16
EPS:-0.23
Operating Margin:0.00
Gross Profit Margin:0.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:98.31
Beta:0.00
Buffet's Owners Earnings:0.00
Price to Owner's Earnings:0.00
About Calidi Biotherapeutics Inc. ( CLDI ) :
Calidi Biotherapeutics, Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is based in San Diego, California.
User Content from Tickernomics. Created by Luminus.
DISCLAIMER

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.